Click here to read the articles and download the PDF

Pharmaceutical Commerce - December 2024

Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts.

Did Industry Fumble the DSCSA Deadline?

A crash course on the bubble itself, including therapeutic areas most affected.

Going Inside the Gross-to-Net Bubble and Its Nuances

Addressing the bottlenecks in cell and gene therapy manufacturing through a well-designed artificial intelligence approach is essential to avoiding data siloes.

Why AI Advances in CGT Require Getting Data Right

Articles

The development and manufacturing plant will be constructed in Texas, and is expected to become operational by Q1 2025.

New pDNA Facility in the Works for Bionova Scientific 

The courts reversed certain key guidance documents issued by the Health Resources and Services Administration for the 340B Program, which raises uncertainty.

Critical Year Ahead for the 340B Drug Pricing Program

The latest news for pharma industry insiders.

Pharma Pulse 6/5/24: Polypharmacy and the Pivotal Role of the Payer, Patients and Data Disrupt the Industry & more

The new plant in Italy is expected to tackle the rise in biopharmaceutical material demand, specifically for GLP-1s.

Stevanato Group Inaugurates Cisterna di Latina Site

A retrospective study explores the connection between adherence and racial/ethnic disparities among patients with Alzheimer’s disease, along with similar dementias.

The Impact of Medicare Part D Antidementia Medication Therapy Management on Adherence

Pharma Pulse 6/4/24: Differentiating Consumer- & Medical-Grade Wearables, Is Your Serialization Program Sustainable? & more

The Netherlands plant is expected to provide solutions that can help further the development of advanced therapies. 

Thermo Fisher Scientific Introduces New EU Ultra-Cold Facility

Videos

In an interview with Pharma Commerce Editor Nicholas Saraceno, Lung-I Cheng, PhD, VP, Head of Cell & Gene Therapy Service Line, Cencora offers his thoughts on Cencora's inaugural ThinkLive Cell and Gene Therapy Summit.  

Cencora VP & Head of Cell & Gene Therapy Service Line Discusses the ThinkLive Cell and Gene Therapy Summit

Pharma Pulse 6/3/24: New ChatGPT Offers Lesson in AI Hype, Managing Diversity & more

Financial commitment will go toward expanding the CDMO’s integrated antibody-drug conjugate services.

Featured Content

Pharmaceutical Commerce - December 2024

Did Industry Fumble the DSCSA Deadline?

Going Inside the Gross-to-Net Bubble and Its Nuances

Why AI Advances in CGT Require Getting Data Right